Covered recipient · General Payments record
NORIDZA RIVERA RODRIGUEZ
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$32,715.59
154 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,743.00 | 7 |
| Consulting Fee | $11,055.00 | 11 |
| Food and Beverage | $3,462.15 | 131 |
| Honoraria | $2,340.00 | 1 |
| Education | $73.44 | 2 |
| Travel and Lodging | $42.00 | 2 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AbbVie Inc. | $13,465.93 | 22 |
| E.R. Squibb & Sons, L.L.C. | $12,111.77 | 34 |
| Merck Sharp & Dohme LLC | $3,084.23 | 14 |
| Rigel Pharmaceuticals, Inc. | $2,485.32 | 6 |
| AstraZeneca Pharmaceuticals LP | $352.42 | 18 |
| PBG PUERTO RICO LLC | $231.84 | 12 |
| Janssen Pharmaceuticals, Inc | $216.17 | 13 |
| GENZYME CORPORATION | $153.06 | 7 |
| Genentech USA, Inc. | $84.85 | 4 |
| Novartis Pharmaceuticals Corporation | $82.31 | 4 |
| Janssen Biotech, Inc. | $64.99 | 1 |
| BeiGene USA, Inc. | $59.80 | 3 |
| CTI BioPharma Corp. | $44.97 | 2 |
| Amgen Inc. | $40.06 | 2 |
| Eisai Inc. | $39.95 | 2 |
| Astellas Pharma US Inc | $28.99 | 1 |
| Mirati Therapeutics, Inc. | $22.95 | 1 |
| PFIZER INC. | $22.45 | 1 |
| SOBI, INC | $20.73 | 1 |
| EMD Serono, Inc. | $20.40 | 1 |
| Eli Lilly Export S.A. Puerto Rico Branch | $20.00 | 1 |
| Incyte Corporation | $19.94 | 1 |
| GlaxoSmithKline, LLC. | $19.69 | 1 |
| Celgene Corporation | $14.36 | 1 |
| ARRAY BIOPHARMA INC | $8.41 | 1 |
Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
NORIDZA RIVERA RODRIGUEZ
NPI 1023210200 · CMS profile ID 591600
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
SAN JUAN, PR
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1023210200?year=2023&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- NORIDZA RIVERA RODRIGUEZ, NPI 1023210200, CMS profile ID 591600. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023210200?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). NORIDZA RIVERA RODRIGUEZ, NPI 1023210200, CMS profile ID 591600. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023210200?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- NORIDZA RIVERA RODRIGUEZ, NPI 1023210200, CMS profile ID 591600, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1023210200?year=2023&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
154 matching records · $32,715.59 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 154.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $5.65 | 04/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014647043 | CMS |
| E.R. Squibb & Sons, L.L.C. | $3.50 | 04/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014647055 | CMS |
| Merck Sharp & Dohme LLC | $14.50 | 04/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048274883 | CMS |
| BeiGene USA, Inc. | $22.27 | 04/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051180193 | CMS |
| Janssen Biotech, Inc. | $64.99 | 04/18/2023 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988370807 | CMS |
| Celgene Corporation | $14.36 | 04/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014647031 | CMS |
| Janssen Pharmaceuticals, Inc | $23.18 | 04/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 987931179 | CMS |
| AbbVie Inc. | $3,375.00 | 04/06/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998625177 | CMS |
| AbbVie Inc. | $27.72 | 04/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998625171 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.09 | 04/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015722275 | CMS |
| AbbVie Inc. | $125.00 | 03/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998625165 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,156.00 | 03/29/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014647153 | CMS |
| PBG PUERTO RICO LLC | $22.47 | 03/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049186991 | CMS |
| GENZYME CORPORATION | $21.80 | 03/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050132147 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,980.00 | 03/27/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014647569 | CMS |
| AbbVie Inc. | $46.81 | 03/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998625147 | CMS |
| AbbVie Inc. | $60.19 | 03/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998625153 | CMS |
| AbbVie Inc. | $20.06 | 03/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998625159 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.25 | 03/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014646973 | CMS |
| E.R. Squibb & Sons, L.L.C. | $121.14 | 03/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014647141 | CMS |
| PBG PUERTO RICO LLC | $17.09 | 03/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049403847 | CMS |
| AbbVie Inc. | $24.90 | 03/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998625141 | CMS |
| Merck Sharp & Dohme LLC | $15.68 | 03/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048274185 | CMS |
| CTI BioPharma Corp. | $24.53 | 03/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1039694797 | CMS |
| Novartis Pharmaceuticals Corporation | $21.95 | 03/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 992883455 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.00 | 03/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011697687 | CMS |
| AstraZeneca Pharmaceuticals LP | $5.25 | 02/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015216243 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.82 | 02/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015682045 | CMS |
| E.R. Squibb & Sons, L.L.C. | $300.00 | 02/27/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014647595 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.80 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011843165 | CMS |
| Merck Sharp & Dohme LLC | $181.34 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048617963 | CMS |
| Janssen Pharmaceuticals, Inc | $18.83 | 02/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 987931163 | CMS |
| Mirati Therapeutics, Inc. | $22.95 | 02/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1058001477 | CMS |
| Eisai Inc. | $16.39 | 02/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1023325917 | CMS |
| Genentech USA, Inc. | $22.02 | 02/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040493557 | CMS |
| E.R. Squibb & Sons, L.L.C. | $21.29 | 02/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014646913 | CMS |
| BeiGene USA, Inc. | $13.00 | 01/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051180195 | CMS |
| Rigel Pharmaceuticals, Inc. | $2,340.00 | 01/28/2023 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1033375727 | CMS |
| Rigel Pharmaceuticals, Inc. | $14.00 | 01/28/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1033375995 | CMS |
| Rigel Pharmaceuticals, Inc. | $42.09 | 01/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1033376005 | CMS |
| Rigel Pharmaceuticals, Inc. | $43.77 | 01/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1033376015 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.05 | 01/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015854191 | CMS |
| E.R. Squibb & Sons, L.L.C. | $30.00 | 01/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014647687 | CMS |
| E.R. Squibb & Sons, L.L.C. | $50.00 | 01/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014647699 | CMS |
| E.R. Squibb & Sons, L.L.C. | $25.00 | 01/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014647709 | CMS |
| E.R. Squibb & Sons, L.L.C. | $35.00 | 01/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014647723 | CMS |
| E.R. Squibb & Sons, L.L.C. | $22.00 | 01/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014647736 | CMS |
| GENZYME CORPORATION | $19.62 | 01/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050132109 | CMS |
| Merck Sharp & Dohme LLC | $13.27 | 01/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048274891 | CMS |
| Novartis Pharmaceuticals Corporation | $15.99 | 01/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 992883453 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $110.00 | 1 |
| PY2025 | Principal investigator | $593,392.98 | 78 |
| PY2024 | Principal investigator | $531,586.35 | 32 |
| PY2023 | Principal investigator | $145,786.62 | 28 |
| PY2022 | Recipient | $1,544.00 | 1 |
| PY2022 | Principal investigator | $237,810.85 | 67 |
| PY2021 | Recipient | $1,619.97 | 1 |
| PY2021 | Principal investigator | $257,306.68 | 116 |
| PY2020 | Principal investigator | $115,422.79 | 22 |
| PY2019 | Principal investigator | $12,650.00 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
79 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $216.00 | 12/31/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting | No dispute reported | 06/30/2026 | 1202534519 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $61,025.56 | 12/31/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials - Ciudadela | A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC That Progressed On or After Prior Treatment with One Next generation Hor | No dispute reported | 06/30/2026 | 1232930321 |
| Principal investigator 1 | AstraZeneca UK Limited | $5,106.00 | 12/05/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease | No dispute reported | 06/30/2026 | 1185537143 |
| Principal investigator 1 | Exelixis Inc. | $459.00 | 12/04/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222383042 |
| Principal investigator 1 | Exelixis Inc. | $8,203.76 | 12/04/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222383044 |
| Principal investigator 1 | Exelixis Inc. | $75.47 | 12/04/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222383046 |
| Principal investigator 1 | Exelixis Inc. | $174.96 | 12/04/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222383050 |
| Principal investigator 1 | Exelixis Inc. | $129.87 | 12/04/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222383052 |
| Principal investigator 1 | Exelixis Inc. | $62.24 | 12/04/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222383056 |
| Principal investigator 1 | Exelixis Inc. | $2,849.61 | 12/04/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222383058 |
| Principal investigator 1 | Exelixis Inc. | $49.95 | 12/04/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222383060 |
| Principal investigator 1 | Exelixis Inc. | $4,672.92 | 12/04/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222383062 |
| Principal investigator 1 | Exelixis Inc. | $72.77 | 12/04/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222383064 |
| Principal investigator 1 | Exelixis Inc. | $90.45 | 12/04/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222383066 |
| Principal investigator 1 | Exelixis Inc. | $2,580.42 | 12/04/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222383070 |
| Principal investigator 1 | Exelixis Inc. | $4,536.00 | 12/04/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222383074 |
| Principal investigator 1 | Exelixis Inc. | $5,140.02 | 12/04/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222383078 |
| Principal investigator 1 | Genentech, Inc. | $874.00 | 12/02/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211636742 |
| Principal investigator 1 | ABBVIE INC. | $325.00 | 12/01/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202526154 |
| Principal investigator 1 | Genmab U.S., Inc. | $760.00 | 11/20/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor (ABBIL1TY MELANOMA-07) | No dispute reported | 06/30/2026 | 1235932905 |
| Principal investigator 1 | Genmab U.S., Inc. | $9,885.72 | 11/20/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor (ABBIL1TY MELANOMA-07) | No dispute reported | 06/30/2026 | 1235932909 |
| Principal investigator 1 | Genmab U.S., Inc. | $2,500.00 | 11/14/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor (ABBIL1TY MELANOMA-07) | No dispute reported | 06/30/2026 | 1235932888 |
| Principal investigator 1 | Genmab U.S., Inc. | $2,538.00 | 11/14/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor (ABBIL1TY MELANOMA-07) | No dispute reported | 06/30/2026 | 1235932893 |
| Principal investigator 1 | Genmab U.S., Inc. | $162.00 | 11/14/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor (ABBIL1TY MELANOMA-07) | No dispute reported | 06/30/2026 | 1235932897 |
| Principal investigator 1 | Genmab U.S., Inc. | $22,000.00 | 11/14/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor (ABBIL1TY MELANOMA-07) | No dispute reported | 06/30/2026 | 1235932901 |
| Principal investigator 1 | Genmab U.S., Inc. | $17,071.98 | 11/14/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor (ABBIL1TY MELANOMA-07) | No dispute reported | 06/30/2026 | 1235932912 |
| Principal investigator 1 | Exelixis Inc. | $6,167.23 | 11/07/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222383040 |
| Principal investigator 1 | Exelixis Inc. | $8,203.76 | 11/07/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222383048 |
| Principal investigator 1 | Exelixis Inc. | $5,140.02 | 11/07/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222383054 |
| Principal investigator 1 | Exelixis Inc. | $6,167.23 | 11/07/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222383068 |
| Principal investigator 1 | Exelixis Inc. | $4,536.00 | 11/07/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222383072 |
| Principal investigator 1 | Exelixis Inc. | $3,375.00 | 11/07/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222383076 |
| Principal investigator 1 | Exelixis Inc. | $4,672.92 | 11/07/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222383080 |
| Principal investigator 1 | ABBVIE INC. | $4,208.00 | 10/23/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202518297 |
| Principal investigator 1 | ABBVIE INC. | $350.00 | 10/23/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202518315 |
| Principal investigator 1 | ABBVIE INC. | $350.00 | 10/17/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202517413 |
| Principal investigator 1 | ABBVIE INC. | $4,680.00 | 10/17/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202517415 |
| Principal investigator 1 | ABBVIE INC. | $3,000.00 | 10/17/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202517417 |
| Principal investigator 1 | Genentech, Inc. | $24,401.00 | 10/15/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211636737 |
| Principal investigator 1 | Genentech, Inc. | $30,600.00 | 09/25/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | INAVO123 | No dispute reported | 06/30/2026 | 1211636694 |
| Principal investigator 1 | PFIZER INC. | $37,050.00 | 09/09/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TR | A PHASE 1B2 OPENLABEL MULTICOHORT STUDY OF DISITAMAB VEDOTIN IN ADULTS WITH HER2 EXPRESSING ADVANCED BREAST CANCER | No dispute reported | 06/30/2026 | 1228802726 |
| Principal investigator 1 | Genentech, Inc. | $9,511.00 | 09/04/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211636731 |
| Principal investigator 1 | ABBVIE INC. | $8,316.00 | 09/03/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202507413 |
| Principal investigator 1 | ABBVIE INC. | $55.00 | 08/21/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202505319 |
| Principal investigator 1 | ABBVIE INC. | $4,848.69 | 08/19/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202505093 |
| Principal investigator 1 | ABBVIE INC. | $5,798.25 | 08/19/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202505095 |
| Principal investigator 1 | ABBVIE INC. | $2,452.45 | 08/15/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202504955 |
| Principal investigator 1 | ABBVIE INC. | $1,461.20 | 08/15/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202504957 |
| Principal investigator 1 | ABBVIE INC. | $474.90 | 08/15/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202504959 |
| Principal investigator 1 | ABBVIE INC. | $5,053.05 | 07/30/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202500452 |
| Principal investigator 1 | ABBVIE INC. | $5,053.05 | 07/30/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202500454 |
| Principal investigator 1 | ABBVIE INC. | $10,783.80 | 07/30/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202500456 |
| Principal investigator 1 | ABBVIE INC. | $5,730.75 | 07/30/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202500458 |
| Principal investigator 1 | ABBVIE INC. | $5,798.25 | 07/30/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202500460 |
| Principal investigator 1 | ABBVIE INC. | $3,858.00 | 07/17/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202498576 |
| Principal investigator 1 | ABBVIE INC. | $5,506.00 | 07/17/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy | No dispute reported | 06/30/2026 | 1202498640 |
| Principal investigator 1 | ABBVIE INC. | $1,532.25 | 06/10/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202490705 |
| Principal investigator 1 | ABBVIE INC. | $810.00 | 06/10/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202490707 |
| Principal investigator 1 | ABBVIE INC. | $3,126.00 | 06/03/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202487983 |
| Principal investigator 1 | ABBVIE INC. | $3,126.00 | 06/03/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202489525 |
| Principal investigator 1 | ABBVIE INC. | $3,976.00 | 06/03/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202489527 |
| Principal investigator 1 | Genentech, Inc. | $30,600.00 | 05/19/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211636722 |
| Principal investigator 1 | ABBVIE INC. | $488.70 | 04/03/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202473541 |
| Principal investigator 1 | ABBVIE INC. | $700.00 | 02/20/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202453015 |
| Principal investigator 1 | ABBVIE INC. | $3,858.00 | 02/20/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202453019 |
| Principal investigator 1 | ABBVIE INC. | $4,749.00 | 02/20/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202453023 |
| Principal investigator 1 | ABBVIE INC. | $350.00 | 02/20/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202453028 |
| Principal investigator 1 | ABBVIE INC. | $4,749.00 | 02/20/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202453086 |
| Principal investigator 1 | ABBVIE INC. | $1,400.00 | 02/20/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202453090 |
| Principal investigator 1 | ABBVIE INC. | $975.00 | 02/13/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202451234 |
| Principal investigator 1 | ABBVIE INC. | $494.10 | 02/13/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202451273 |
| Principal investigator 1 | ABBVIE INC. | $2,020.95 | 01/29/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202441819 |
| Principal investigator 1 | ABBVIE INC. | $494.10 | 01/29/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202441823 |
| Principal investigator 1 | BeiGene, Ltd. | $1,400.00 | 01/28/2025 | Non-covered Recipient Entity Pan American Oncology Trials, LLC | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190322662 |
| Principal investigator 1 | BeiGene, Ltd. | $3,000.00 | 01/28/2025 | Non-covered Recipient Entity Pan American Oncology Trials, LLC | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190322664 |
| Principal investigator 1 | BeiGene, Ltd. | $6,450.00 | 01/28/2025 | Non-covered Recipient Entity Pan American Oncology Trials, LLC | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190322666 |
| Recipient | ABBVIE INC. | $110.00 | 01/23/2025 | Covered Recipient Physician | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202400776 |
| Principal investigator 1 | ABBVIE INC. | $5,730.75 | 01/23/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202441050 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $144,199.88 | 01/09/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials Llc | Phase 1b Single Arm, Open-label Trial of RYZ101 in Combination With Carboplatin + Etoposide + Atezolizumab in Subjects With Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC) | No dispute reported | 06/30/2026 | 1235994790 |